1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (713) 794-4297
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases
Article first published online: 1 APR 2003
DOI: 10.1002/cncr.11315
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Giles, F. J., Cooper, M. A., Silverman, L., Karp, J. E., Lancet, J. E., Zangari, M., Shami, P. J., Khan, K. D., Hannah, A. L., Cherrington, J. M., Thomas, D. A., Garcia-Manero, G., Albitar, M., Kantarjian, H. M. and Stopeck, A. T. (2003), Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases. Cancer, 97: 1920–1928. doi: 10.1002/cncr.11315
Publication History
- Issue published online: 1 APR 2003
- Article first published online: 1 APR 2003
- Manuscript Accepted: 30 DEC 2002
- Manuscript Revised: 13 DEC 2002
- Manuscript Received: 23 OCT 2002
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , The bone marrow stroma in hematological neoplasms—a guilty bystander, Nature Reviews Clinical Oncology, 2011, 8, 8, 456
- 2, , , , , , Active tumor targeting drug delivery system: the current status, Academic Journal of Second Military Medical University, 2010, 30, 3, 321
- 3, , , , , , , , Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis, Clinical Lymphoma, Myeloma & Leukemia, 2010, 10, 4, 285
- 4, , , , , , Phase II Study of Sunitinib in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis, Clinical Lymphoma, Myeloma & Leukemia, 2010, 10, 4, 281
- 5, , Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly, Cancer Treatment Reviews, 2009, 35, 2, 97
- 6, , , , , , , , , A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders, Leukemia Research, 2008, 32, 1, 71
- 7, , Choosing between stem cell therapy and drugs in myelofibrosis, Leukemia, 2008, 22, 3, 474
- 8, , , FLT3 inhibitors in acute myeloid leukemia, Expert Review of Hematology, 2008, 1, 2, 153
- 9, , , , , Hemostatic complications of angiogenesis inhibitors in cancer patients, American Journal of Hematology, 2008, 83, 11Direct Link:
- 10, , , , , , , , , Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia, Hematology, 2008, 13, 1, 1
- 11, , , Autocrine VEGF loops, signaling pathways, and acute leukemia regulation, Leukemia & Lymphoma, 2007, 48, 3, 481
- 12, , , Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia, Current Hematologic Malignancy Reports, 2007, 2, 1, 25
- 13
- 14, Myelofibrosis: biology and treatment options, European Journal of Haematology, 2007, 79,Direct Link:
- 15, , , New and Old Treatment Modalities in Primary Myelofibrosis, The Cancer Journal, 2007, 13, 6, 377
- 16, , , , , , , , , , , , PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia, Leukemia Research, 2007, 31, 7, 891
- 17, , Targeted therapy in advanced colorectal cancer, an update, Targeted Oncology, 2007, 2, 3, 165
- 18, The dawn of targeted therapy for primary myelofibrosis: Opportunities and challenges, Leukemia Research, 2007, 31, 7, 883
- 19, , , , , FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia, STEM CELLS, 2006, 24, 5Direct Link:
- 20, , Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias, Annals of Hematology, 2006, 85, 3, 139
- 21, , Treatment of Older Patients With Acute Myeloid Leukemia—New Agents, Seminars in Hematology, 2006, 43, 2, 96
- 22, , , , , , , , , Angiogenesis Inhibitor Z24 Induces Endothelial Cell Apoptosis and Suppresses Tumor Growth and Metastasis, Journal of Pharmacological Sciences, 2005, 97, 4, 533
- 23, , , , , Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients, British Journal of Haematology, 2005, 129, 6Direct Link:
- 24, , Emerging drugs for the treatment of myelodysplastic syndrome, Expert Opinion on Emerging Drugs, 2005, 10, 3, 569
- 25, Modern management of myelofibrosis, British Journal of Haematology, 2005, 128, 5Direct Link:
- 26, , , , , New approaches in the treatment of myelofibrosis, Cancer, 2005, 103, 1Direct Link:
- 27, , , , Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit, STEM CELLS, 2005, 23, 1Direct Link:
- 28
- 29, Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia, Current Opinion in Hematology, 2005, 12, 1, 55
- 30, , , , Accelerated and blastic phases of chronic myelogenous leukemia, Hematology/Oncology Clinics of North America, 2004, 18, 3, 753
- 31, , , Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia, Leukemia & Lymphoma, 2004, 45, 12, 2373
- 32, , , , , , , , , , , , Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine, European Journal of Pharmacology, 2004, 498, 1-3, 9
- 33, , Chemical genetics for therapeutic target mining, Expert Opinion on Therapeutic Targets, 2004, 8, 6, 653
- 34, , , , , , , , , , , , , Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia, Leukemia Research, 2004, 28, 7, 679
- 35, Inhibitors of signaling in myelodysplastic syndrome, Best Practice & Research Clinical Haematology, 2004, 17, 4, 613
- 36, , Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction, Expert Review of Anticancer Therapy, 2004, 4, 3, 387
- 37, , , Novel therapies for patients with chronic myeloid leukemia, Expert Review of Anticancer Therapy, 2004, 4, 2, 271
- 38, , , , , , , , , , , Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders, Clinical & Laboratory Haematology, 2004, 26, 4Direct Link:
- 39, , , , , , , , , , , SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells, Journal of Hepatology, 2004, 41, 2, 267
- 40, , Angiogenic tumor markers, antiangiogenic agents and radiation therapy, Expert Review of Anticancer Therapy, 2003, 3, 3, 357
- 41
- 42, , Novel FLT3 tyrosine kinase inhibitors, Expert Opinion on Investigational Drugs, 2003, 12, 12, 1951
- 43, , Protein Kinase Inhibitors in Drug Discovery, Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing,Direct Link: